Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
1. CRL's Q2 2025 revenue rose 0.6%, beating estimates despite currency impacts. 2. Operating margin fell to 9.7%, while adjusted earnings increased by 11.4%. 3. PETA investigations into animal practices were cleared, reducing regulatory concerns. 4. 2025 revenue outlook lowered, but adjusted earnings guidance raised to $9.90-$10.30. 5. CRL stock dropped 4.82% post-earnings release, closing at $159.42.